Literature DB >> 12269383

Passive immunization against nicotine attenuates nicotine discrimination.

David H Malin1, Candice L Alvarado, Katherine S Woodhouse, Hilary Karp, Evelyn Urdiales, Diana Lay, Phillip Appleby, William D Moon, Sofiane Ennifar, Lisa Basham, Ali Fattom.   

Abstract

Ten rats were trained in a two lever operant chamber to press different levers after a nicotine injection (0.14 mg/kg s.c.) or a saline injection on an FR10 schedule. The rats were then injected i.p. with either 150 mg nicotine-specific IgG or the same amount of control IgG from non-immunized rabbits. On successive days, they were retested with both levers active after a saline injection, a full training dose of nicotine and a half dose of nicotine (0.07 mg/kg s.c.). After saline injection, both groups pressed the saline lever almost exclusively. After each of the nicotine doses, the immunized rats performed a significantly lower percentage of their lever presses on the nicotine lever than did non-immunized rats. The results suggest that passive immunization can interfere with the stimulus properties of nicotine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269383     DOI: 10.1016/s0024-3205(02)01523-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Authors:  Mark G LeSage; David Shelley; Marco Pravetoni; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2012-04-04       Impact factor: 3.533

2.  Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.

Authors:  Mark G LeSage; Daniel E Keyler; Yoko Hieda; Greg Collins; Danielle Burroughs; Chap Le; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2005-07-01       Impact factor: 4.530

Review 3.  Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.

Authors:  Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

4.  Changes in maternal and fetal nicotine distribution after maternal administration of monoclonal nicotine-specific antibody to rats.

Authors:  D E Keyler; M G Lesage; M B Dufek; P R Pentel
Journal:  Int Immunopharmacol       Date:  2006-08-04       Impact factor: 4.932

5.  Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.

Authors:  Irina Esterlis; Jonas O Hannestad; Evgenia Perkins; Frederic Bois; D Cyril D'Souza; Rachel F Tyndale; John P Seibyl; Dorothy M Hatsukami; Kelly P Cosgrove; Stephanie S O'Malley
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

Review 6.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

7.  Enhanced immunogenicity of a bivalent nicotine vaccine.

Authors:  D E Keyler; S A Roiko; C A Earley; M P Murtaugh; P R Pentel
Journal:  Int Immunopharmacol       Date:  2008-07-24       Impact factor: 4.932

8.  Formulation of Nanovaccines toward an Extended Immunity against Nicotine.

Authors:  Yun Hu; Zongmin Zhao; Marion Ehrich; Chenming Zhang
Journal:  ACS Appl Mater Interfaces       Date:  2021-06-09       Impact factor: 10.383

Review 9.  Nicotine vaccines to assist with smoking cessation: current status of research.

Authors:  Tobias Raupach; Philippe H J Hoogsteder; Constant P Onno van Schayck
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

10.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.